A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
← catalyst calendarNCT07533942 · readout in 798 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Chimerix, Inc..
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-16 | actual | When the study began enrolling |
| Primary completion | 2028-10-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-10-16 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Meningioma
Intervention
- Drug: JZP3507 — also filed as ONC206
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (ORR) as Assessed by Response Assessment in Neuro-Oncology (RANO) Criteria and Evaluated by Blinded Independent Central Review (BICR)
measured From first dose until death, withdrawal of consent, or lost to follow-up, up to 36 months.
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed